Molecular Diagnostics raises $2.6 million for InPath:
This article was originally published in Clinica
Executive Summary
Molecular Diagnostics has raised $2.6m financing, which it will use to advance the development of its automated cervical cancer screening product, the InPath system. The funding will also support ongoing negotiations with potential distribution partners for InPath, the Chicago-based company says.